JP2014224079A - 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 - Google Patents
打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 Download PDFInfo
- Publication number
- JP2014224079A JP2014224079A JP2013104797A JP2013104797A JP2014224079A JP 2014224079 A JP2014224079 A JP 2014224079A JP 2013104797 A JP2013104797 A JP 2013104797A JP 2013104797 A JP2013104797 A JP 2013104797A JP 2014224079 A JP2014224079 A JP 2014224079A
- Authority
- JP
- Japan
- Prior art keywords
- tableting
- granules
- drug substance
- candesartan cilexetil
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 45
- 239000006191 orally-disintegrating tablet Substances 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 47
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960004349 candesartan cilexetil Drugs 0.000 claims abstract description 29
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 27
- 235000010355 mannitol Nutrition 0.000 claims abstract description 24
- 239000006185 dispersion Substances 0.000 claims abstract description 22
- 239000002245 particle Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000314 lubricant Substances 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
- 239000011230 binding agent Substances 0.000 claims abstract description 6
- 238000000748 compression moulding Methods 0.000 claims abstract description 3
- 229940088679 drug related substance Drugs 0.000 claims description 26
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 7
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 6
- 239000001069 triethyl citrate Substances 0.000 claims description 6
- 235000013769 triethyl citrate Nutrition 0.000 claims description 6
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 abstract description 9
- 238000005507 spraying Methods 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- 230000000052 comparative effect Effects 0.000 description 13
- 239000003826 tablet Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 229920003117 medium viscosity grade hydroxypropyl cellulose Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- UEJMFQHOVKQHHB-UHFFFAOYSA-N CC(OC(c(cccc1N2)c1N(Cc(cc1)ccc1-c(cccc1)c1-c1nnn[nH]1)C2=O)=O)OC(OC1CCCCC1)=O Chemical compound CC(OC(c(cccc1N2)c1N(Cc(cc1)ccc1-c(cccc1)c1-c1nnn[nH]1)C2=O)=O)OC(OC1CCCCC1)=O UEJMFQHOVKQHHB-UHFFFAOYSA-N 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Abstract
Description
D−マンニトールの顆粒としては、「ノンパレル−108」(フロイント産業株式会社製)を用いた。「ノンパレル−108」は、D−マンニトール含有量が100%であり、粒度範囲は75〜150μmの球状顆粒であった。
「ノンパレル−108」の代わりに粉末状のD−マンニトールとして「Pearlitol 50C」(Roquette Freres,Lestrem、フランス)を用いた以外は、実施例と同様にして固体医薬組成物を得た。なお、比較例の固体医薬組成物を得るための圧縮工程においては、実施例では見られなかったキャッピング等の打錠障害が見られた。「Pearlitol 50C」の平均粒径は50μmであった。
Claims (9)
- 粒度範囲が75〜150μmであるD−マンニトール顆粒と、カンデサルタンシレキセチルと、少なくとも結合剤とを含む打錠用顆粒。
- 粒度範囲が75〜150μmであるD−マンニトール顆粒に、カンデサルタンシレキセチルと少なくとも結合剤とを含む原薬分散液を噴霧し、乾燥してなる、請求項1に記載の打錠用顆粒。
- 原薬分散液がクエン酸トリエチルをさらに含んでいる、請求項2に記載の打錠用顆粒。
- 原薬分散液がドデシル硫酸ナトリウムをさらに含んでいる、請求項3に記載の打錠用顆粒。
- D−マンニトール顆粒100重量部あたり、カンデサルタンシレキセチル1ないし20重量部を含む原薬分散液が噴霧されている、請求項1から請求項4までのいずれか1項に記載の打錠用顆粒。
- 粒度範囲75〜150μmのD−マンニトール顆粒を流動層造粒機内に流動させ、これに少なくとも結合剤を溶解した水または含水エタノールにカンデサルタンシレキセチルを分散した原薬分散液を噴霧し、乾燥することを含む打錠用顆粒の製造方法。
- D−マンニトール顆粒100重量部あたり、カンデサルタンシレキセチル1ないし20重量部に相当する原薬分散液が噴霧される請求項5に記載の方法。
- 原薬分散液がクエン酸トリエチルおよび任意にドデシル硫酸ナトリウムをさらに含んでいる、請求項6または請求項7に記載の方法。
- 請求項1から請求項5までのいずれか1項に記載の顆粒と、少なくとも賦形剤、崩壊剤および滑沢剤との混合物を圧縮成形してなる口腔内崩壊錠。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013104797A JP6126456B2 (ja) | 2013-05-17 | 2013-05-17 | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013104797A JP6126456B2 (ja) | 2013-05-17 | 2013-05-17 | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014224079A true JP2014224079A (ja) | 2014-12-04 |
JP6126456B2 JP6126456B2 (ja) | 2017-05-10 |
Family
ID=52123068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013104797A Active JP6126456B2 (ja) | 2013-05-17 | 2013-05-17 | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6126456B2 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018517715A (ja) * | 2015-06-18 | 2018-07-05 | ミトラ ファーマシューティカルズ エス.エー.Mithra Pharmaceuticals S.A. | エステトロールを含有する口腔内崩壊錠 |
WO2021002411A1 (ja) * | 2019-07-04 | 2021-01-07 | 沢井製薬株式会社 | 口腔内崩壊錠の製造方法及び口腔内崩壊錠 |
WO2021187608A1 (ja) * | 2020-03-18 | 2021-09-23 | ノーベルファーマ株式会社 | 新規顆粒剤及びその製造方法 |
US11147771B2 (en) | 2015-06-18 | 2021-10-19 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
US11452733B2 (en) | 2018-04-19 | 2022-09-27 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
US11484539B2 (en) | 2018-04-19 | 2022-11-01 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
US11957694B2 (en) | 2015-06-18 | 2024-04-16 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003034655A (ja) * | 2001-05-15 | 2003-02-07 | Takeda Chem Ind Ltd | 速崩壊性固形製剤 |
-
2013
- 2013-05-17 JP JP2013104797A patent/JP6126456B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003034655A (ja) * | 2001-05-15 | 2003-02-07 | Takeda Chem Ind Ltd | 速崩壊性固形製剤 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018517715A (ja) * | 2015-06-18 | 2018-07-05 | ミトラ ファーマシューティカルズ エス.エー.Mithra Pharmaceuticals S.A. | エステトロールを含有する口腔内崩壊錠 |
US10888518B2 (en) | 2015-06-18 | 2021-01-12 | Estetra Sprl | Orodispersible tablet containing estetrol |
US11147771B2 (en) | 2015-06-18 | 2021-10-19 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
US11793760B2 (en) | 2015-06-18 | 2023-10-24 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
US11957694B2 (en) | 2015-06-18 | 2024-04-16 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
US11964055B2 (en) | 2015-06-18 | 2024-04-23 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
US11452733B2 (en) | 2018-04-19 | 2022-09-27 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
US11484539B2 (en) | 2018-04-19 | 2022-11-01 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
US11666585B2 (en) | 2018-04-19 | 2023-06-06 | Estetra Srl | Compounds and their uses for alleviating menopause-associated symptoms |
WO2021002411A1 (ja) * | 2019-07-04 | 2021-01-07 | 沢井製薬株式会社 | 口腔内崩壊錠の製造方法及び口腔内崩壊錠 |
WO2021187608A1 (ja) * | 2020-03-18 | 2021-09-23 | ノーベルファーマ株式会社 | 新規顆粒剤及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP6126456B2 (ja) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6126456B2 (ja) | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 | |
EP2777696B1 (en) | Preparation of stable pharmaceutical dosage forms | |
EP3437646A1 (en) | Oral preparation having exceptional elutability | |
JP6679495B2 (ja) | 免疫抑制製剤 | |
JP6895779B2 (ja) | アジルサルタン含有固形医薬組成物 | |
KR20130041144A (ko) | 데페라시록스의 경구투여용 제제 | |
JP2012503613A (ja) | コンパクト化シナカルセット | |
WO2010047381A1 (ja) | 4,5-エポキシモルヒナン誘導体を含有する安定な錠剤 | |
EP2295040B1 (en) | Pharmaceutical compositions of pramipexole | |
EP2804588B1 (en) | Method for producing cinacalcet compositions for direct tableting | |
EP3177290B1 (en) | Pharmaceutical compositions of edoxaban | |
JP2016104812A (ja) | ロキソプロフェンナトリウム及びトラネキサム酸を含有する固形製剤 | |
JP6630343B2 (ja) | 抗酸化剤を含有する固形製剤 | |
WO2016175230A1 (ja) | 経口投与用医薬組成物 | |
JP2015182991A (ja) | 口腔内崩壊錠 | |
JP5680607B2 (ja) | 安定固形製剤及びその製造法 | |
JP2014037356A (ja) | カンデサルタンシレキセチル経口製剤 | |
JP6106359B2 (ja) | ロキソプロフェンナトリウムとビタミンb1を含有する固形製剤 | |
RU2377989C2 (ru) | Лекарственное средство триметазидина в форме матриксной таблетки с пролонгированным действием и способ его получения | |
RU2007147953A (ru) | Фармацевтические рецептуры микронизированного (4-хлорфенил)[4-(4-пиридилметил)-фталазин-1-ила] и его солей с немедленным высвобождением и высоким содержанием лекарственного средства | |
JP4573542B2 (ja) | ビタミンb1誘導体組成物 | |
JP6112765B2 (ja) | ロキソプロフェンナトリウム及びdl−メチルエフェドリン塩酸塩を含有する固形製剤 | |
JP2007031377A (ja) | 服用性に優れたグリメピリド含有薬剤 | |
JP6002870B1 (ja) | 低用量薬物を含有する口腔内崩壊錠 | |
JP6451310B2 (ja) | 固形医薬組成物及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160405 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170310 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170404 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170407 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6126456 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |